UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): Nov ember 5, 2019 (November 5, 2019)
ALLERGAN PLC
(Exact Name of Registrant as Specified in Charter)
| | | | |
Ireland | | 001-36867 | | 98-1114402 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
|
Clonshaugh Business and Technology Park |
Coolock, Dublin, D17 E400, Ireland |
(Address of Principal Executive Offices) |
(862) 261-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Exchange Act:
| | | | |
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Ordinary Share, par value $0.0001 per share | | AGN | | New York Stock Exchange |
Floating rate notes due 2020 | | AGN20A | | New York Stock Exchange |
0.500% notes due 2021 | | AGN21 | | New York Stock Exchange |
1.500% notes due 2023 | | AGN23A | | New York Stock Exchange |
1.250% notes due 2024 | | AGN24A | | New York Stock Exchange |
2.625% notes due 2028 | | AGN28 | | New York Stock Exchange |
2.125% notes due 2029 | | AGN29 | | New York Stock Exchange |
| Item 2.02 | Results of Operations and Financial Condition. |
On November 5, 2019, Allergan plc (the “Company”) posted an investor FAQ entitled “Third Quarter 2019 Financial Results – Frequently Asked Questions” (the “Investor FAQ”) to the investor relations section of its website. The Investor FAQ is related to the Company’s earnings release for the quarter ended September 30, 2019. A copy of the Investor FAQ is attached hereto as an exhibit 99.1 and incorporated herein by reference.
The information in this report (including the exhibit) is furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| | | | |
Exhibit | | | Description of Exhibit |
| | | | | |
| | Exhibit 99.1 | | | Investor FAQ |
| | | | | |
| | Exhibit 104 | | | Cover Page Interactive Data File (embedded within the Inline XBRL Document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
Dated: November 5, 2019 | | | | Allergan plc |
| | | | | | | |
| | | | By: | | /s/ A. Robert D. Bailey |
| | | | | | A. Robert D. Bailey |
| | | | | | EVP and Chief Legal Officer and Corporate Secretary |
